- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Business Development Office
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Novel mucolytics for the treatment of respiratory diseases
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Partnerships and collaborations
- Royalties distribution
- Start-up companies
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Development of tau-specific therapeutic and diagnostic antibodies
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Facioscapulohumeral muscular dystrophy

Facioscapulohumeral muscular dystrophy (FSHD) is a progressive muscle wasting disease that weakens the face, arm and shoulders. The condition affects more than 1000 people in Australia and currently has no treatment or cure.
Our researchers are making critical discoveries about the cause of FSHD that could lead to therapies for this debilitating condition.
FSHD research at WEHI
Our researchers are:
- Investigating the genes that are dysfunctional in people with FSHD
- Studying the epigenetic pathways that contribute to FSHD
- Performing screens to find drugs to treat or prevent FSHD
What is FSHD?
FSHD is a disease characterised by death of muscle cells and tissue leading to progressive muscle weakness. The name FSHD refers to the muscles typically affected:
- Face (facio)
- Shoulders (scapula)
- Upper arm (humeral)
The condition can appear at any time from infancy until a person is in their 50s, but is most commonly diagnosed in teenagers and young adults.
The condition usually progresses slowly, often with long periods of stability. Eventually, however, the loss of muscle strength can be extremely debilitating, resulting in difficulty walking, talking, smiling and eating.
Although most people with FSHD have a normal life expectancy, they can experience chronic pain, fatigue, loss of independence and social isolation due to their condition.
Symptoms of FSHD
The symptoms of FSHD are due to muscle weakness and may include:
- Inability to smile, whistle, close eyes completely (weak facial muscles)
- Difficulty throwing a ball, shoulder blades that “wing” out (weak shoulder blades)
- Loss of upper arm strength
- Protuberant abdomen, excessive curve in lower back (weak abdomal muscles)
- Weak leg muscles
- Foot drop (foot muscle weakness)
- Muscle pain
- Fatigue
The symptoms range in severity: some people are relatively unaffected by the condition, while others eventually require a wheelchair.
FSHD that presents during infancy is usually more severe than adult-onset FSHD and may also include hearing and vision loss. Men with FSHD tend to show an earlier onset of disease and worse symptoms than women.
Cause of FSHD
FSHD is an inherited disease, meaning it is caused by a change in DNA (genetic mutation) transmitted from parents to their children. Parents with the mutation have a 50 per cent chance of passing the condition on to each child.
There are two subtypes of FSHD caused by different genetic mutations:
- FSHD1 is due to a reduced number of copies of a DNA segment on chromosome 4. This is the most common type of FSHD.
- FSHD2 is caused by mutation in SMCHD1, a gene discovered by WEHI researchers.
Both mutations lead to production of a protein that is toxic to muscle cells, leading to progressive muscle weakening.
How is FSHD treated?
There is currently no specific treatment or cure for FSHD. Approaches to manage the disease and alleviate symptoms include:
- Physiotherapy
- Exercise
- Diet
- Pain medication
- Speech therapy
- Surgery
Searching for a treatment
Scientists at WEHI are working towards developing targeted drugs for FSHD. Their work focuses on the gene SMCHD1, which is faulty in people with FSHD2. SMCHD1 is an epigenetic regulator that normally switches off expression of a protein that destroys muscle. Restoring SMCHD1 activity could potentially switch off the toxic protein and protect muscle function.
Our researchers are currently screening thousands of drug-like molecules in search of chemicals that boost SMCHD1 activity. Promising molecules will then be refined to develop drugs to treat FSHD or even prevent the disease in people carrying FSHD mutations.
Support for people with FSHD
WEHI researchers are not able to provide specific medical advice to individuals. For further information, please visit the FSHD Global Research Foundation, Muscular Dystrophy Australia or consult your medical specialist.
Researchers:
Super Content:
Researchers have made a critical discovery about a gene which is dysfunctional in people with a form of muscular dystrophy called FSHD2.
A genetic change discovered in babies born without a nose could help to prevent a debilitating and incurable form of muscular dystrophy.
A search for drugs to treat muscular dystrophy is being supported by a grant from the FSHD Global Research Foundation.
Researchers have discovered how a protein called SMCHD1 controls healthy development.
WEHI.TV animation: X inactivation is a vital process that occurs in all DNA-containing cells of the female body. It is also an important research model and tool for studying epigenetics.